Single dose pharmacokinetics of atorvastatin oral formulations using a simple HPLC-UV method

The study was aimed to assess pharmacokinetics of atorvastatin (40 mg) in healthy fasted human subjects by a simple and inexpensive high performance liquid chromatography. Experimental design of the study was a randomized, two way, two periods, crossover study (single dose in fasted conditions). Eighteen (18) healthy male volunteers were enrolled according to FDA guidelines. The plasma samples were assayed using an isocratic High Performance Liquid Chromatography (HPLC) system of Agilent technologies USA consisted of an isocratic pump with column of Thermo Electron Corporation USA (ODS hypersil C18 4.6 mm x 250 mm), a UV-visible detector set at ?max 237 nm. Maximum plasma concentrations (Cmax) of atorvastatin (Mean ± SEM) for the reference product (A) found to be 13.739±0.210ng/ml & 13.374±0.145ng/ml for test product (B). Tmax values (Mean±SEM) of atorvastatin were 1.222±0.060 hours and 1.167±0.057hours for reference and test products, respectively. The values of AUC0-? (Mean ± SEM) for the reference (A) and test product (B) were 73.955±1.715ng.h/ml and 77.773±1.858ng. h/ml, respectively. Other pharmacokinetic parameters of both products were also determined. A statistical non-significant difference between pharmacokinetic parameters has been found and both brands of atorvastatin showed the same rate and extent of absorption in healthy fasted human volunteers after single dose. A simple and cost effective HPLC method was developed and applied.